Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications

Author(s): Jorge Penalver*, Maxwell Ambrosino, Hee D. Jeon, Akanksha Agrawal, Napatt Kanjanahattakij, Marie Pitteloud, Jessica Stempel, Aman Amanullah

Journal Name: Current Cardiology Reviews

Volume 16 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: There is a growing interest in the observed significant incidence of transthyretin cardiac amyloidosis in elderly patients with aortic stenosis. Approximately, 16% of patients with severe aortic stenosis undergoing aortic valve replacement have transthyretin cardiac amyloidosis. Outcomes after aortic valve replacement appear to be worst in patients with concomitant transthyretin cardiac amyloidosis.

Methods: Publications in PubMed, Cochrane Library, and Embase databases were systematically searched from January 2012 to September 2018 using the keywords transthyretin, amyloidosis, and aortic stenosis. All studies published in English that reported the prevalence, association and outcomes of transthyretin cardiac amyloidosis in patients with aortic stenosis undergoing were included.

Results/Conclusion: The relationship between aortic stenosis and transthyretin cardiac amyloidosis is not well understood. A few studies have proven successful surgical management when both conditions coexist. This systematic review suggests that transthyretin cardiac amyloidosis is common in elderly patients with aortic stenosis and tend to have high mortality rates after AVR. The significant incidence of the two diseases occurring simultaneously warrants further investigation to improve management strategies in the future.

Keywords: Aortic stenosis, transthyretin, cardiac amyloidosis, aortic valve replacement, left ventricular myocardium, hereditary amyloidosis.

[1]
Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and cotran pathologic basis of disease. Philadelphia. Elsevier Saunders 2005; 258-259: 554-6.
[2]
Lindman BR, Clavel MA, Mathieu P, et al. Calcific aortic stenosis. Nat Rev Dis Primers 2016; 2: 16006.
[http://dx.doi.org/10.1038/nrdp.2016.6] [PMID: 27188578]
[3]
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016; 387(10038): 2641-54.
[http://dx.doi.org/10.1016/S0140-6736(15)01274-X] [PMID: 26719234]
[4]
Galat A, Guellich A, Bodez D, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J 2016; 37(47): 3525-31.
[http://dx.doi.org/10.1093/eurheartj/ehw033] [PMID: 26908951]
[5]
Osnabrugge, Ruben LJ, et al. Aortic stenosis in the elderly: Disease prevalence and number of candidates for transcatheter aortic valve replacement: A meta-analysis and modeling study. J Am Coll Cardiol 2013. 62.11: 1002-12..
[6]
Thaden JJ, Nkomo VT, Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis 2014; 56(6): 565-71.
[http://dx.doi.org/10.1016/j.pcad.2014.02.006] [PMID: 24838132]
[7]
Cavalcante João L, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 2017; 191: 98.
[http://dx.doi.org/10.1186/s12968-017-0415-x]
[8]
Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol 2018; 270: 192-6.
[http://dx.doi.org/10.1016/j.ijcard.2018.06.006] [PMID: 29903517]
[9]
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(22): e57-e185.
[http://dx.doi.org/10.1016/j.jacc.2014.02.536] [PMID: 24603191]
[10]
Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017; 38(38): 2879-87.
[http://dx.doi.org/10.1093/eurheartj/ehx350] [PMID: 29019612]
[11]
Bonow Robert O. Greenland Philip. Population-wide trends in aortic stenosis incidence and outcomes. Circulation 2015.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.014846]
[12]
Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006; 166(17): 1805-13.
[http://dx.doi.org/10.1001/archinte.166.17.1805] [PMID: 17000935]
[13]
Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med 2015; 128(12): 1275-80.
[http://dx.doi.org/10.1016/j.amjmed.2015.05.039] [PMID: 26091765]
[14]
Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2018; 45(11): 1945-55.
[http://dx.doi.org/10.1007/s00259-018-4013-4] [PMID: 29687207]
[15]
Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996; 98: 236-8.
[http://dx.doi.org/10.1007/s004390050199] [PMID: 8698351]
[16]
Pinney Jennifer H, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013; 22e000098
[http://dx.doi.org/10.1161/JAHA.113.000098]
[17]
Eriksson M, Büttner J, Todorov T, et al. Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid. Am J Surg Pathol 2009; 33(1): 58-65.
[http://dx.doi.org/10.1097/PAS.0b013e3181788566] [PMID: 18830126]
[18]
Java AP, Greason KL, Dispenzieri A, et al. Aortic valve replacement in patients with amyloidosis. J Thorac Cardiovasc Surg 2018; 156(1): 98-103.
[http://dx.doi.org/10.1016/j.jtcvs.2017.12.048] [PMID: 29397971]
[19]
Longhi S, Lorenzini M, Gagliardi C, et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2016; 9(3): 325-7.
[http://dx.doi.org/10.1016/j.jcmg.2015.04.012] [PMID: 26189123]
[20]
Scully PR, Treibel TA, Fontana M, et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol 2018; 71(4): 463-4.
[http://dx.doi.org/10.1016/j.jacc.2017.11.037] [PMID: 29389364]
[21]
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95(4): 535-7.
[http://dx.doi.org/10.1016/j.amjcard.2004.10.028] [PMID: 15695149]
[22]
Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66(21): 2451-66.
[http://dx.doi.org/10.1016/j.jacc.2015.09.075] [PMID: 26610878]
[23]
Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016; 16(1): 129.
[http://dx.doi.org/10.1186/s12872-016-0311-6] [PMID: 27267362]
[24]
Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiacamyloid in severe calcific aortic stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 2016; 9(8)e005066
[http://dx.doi.org/10.1161/CIRCIMAGING.116.005066] [PMID: 27511979]
[25]
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133(24): 2404-12.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021612] [PMID: 27143678]
[26]
Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med 2015; 47(8): 625-38.
[http://dx.doi.org/10.3109/07853890.2015.1068949] [PMID: 26611723]
[27]
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126(10): 1286-300.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.078915] [PMID: 22949539]
[28]
Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation 2012; 126(12): e178-82.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.069195] [PMID: 22988049]
[29]
González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol (Engl Ed) 2017; 70(11): 991-1004.
[http://dx.doi.org/10.1016/j.rec.2017.05.036] [PMID: 28870641]
[30]
Dahm Cherie N, Cornell R. Frank, Lenihan Daniel J. Advances in treatment of cardiac amyloid. Current treatment options in cardiovascular medicine 2018; 20(5): 37.
[http://dx.doi.org/10.1007/s11936-018-0631-1]
[31]
Scully PR, Treibel TA, Fontana M, et al. 1 A multi-centre study of cardiac amyloidosis in tavi patients. Heart 2018; 104: A15.
[32]
Nemshah Yaser. Amyloid heart disease. US Cardiol Rev 2018; 12(2)
[http://dx.doi.org/10.15420/usc.2018.5.1]
[33]
Hommet C, Mondon K, Camus V, et al. Neuroinflammation and β amyloid deposition in Alzheimer’s disease: in vivo quantification with molecular imaging. Dement Geriatr Cogn Disord 2014; 37(1-2): 1-18.
[http://dx.doi.org/10.1159/000354363] [PMID: 24107621]
[34]
Gorevic PD. Amyloid and inflammation. Proc Natl Acad Sci USA 2013; 110(41): 16291-92.
[35]
McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 2013; 126(4): 479-97.
[http://dx.doi.org/10.1007/s00401-013-1177-7] [PMID: 24052108]
[36]
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379(11): 1007-16.
[http://dx.doi.org/10.1056/NEJMoa1805689] [PMID: 30145929]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2020
Page: [221 - 230]
Pages: 10
DOI: 10.2174/1573403X15666190722154152
Price: $65

Article Metrics

PDF: 49
HTML: 2